Advertisement
Advertisement
   
Psychiatric News
PsychoPharm APA logo
Send Feedback   l   View Online
Current News      |      PN Archives      |      News Alert      |      News Update APRIL 21, 2017
EXPERT'S CORNER

Point-of-Care EEG Device Could Ease Efforts to Detect Delirium

Gen Shinozaki, M.D. Gen Shinozaki, M.D., explains the advantages of using bispectral electroencephalogram (EEG) to assess and monitor delirium.

IN THIS ISSUE

FDA Approves First Medication to Treat Tardive Dyskinesia

Ingrezza Ingrezza, a novel and highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is the first and only FDA-approved product for this condition.
   

Aripiprazole May Reduce Some Side Effects of Antipsychotics in Women

Women talking The addition of aripiprazole to an antipsychotic regimen may lead to greater treatment adherence in women experiencing sexual dysfunction and more.
   

INDUSTRY BRIEFS

FDA Approves Handheld VNS Device for Cluster Headaches


The Food and Drug Administration on Tuesday approved a handheld, noninvasive vagus nerve stimulator (VNS) for the treatment of pain associated with episodic cluster headache in adult patients, according to a release by electroCore, the makers of the technology. The device, known as gammaCore, transmits a mild electrical stimulation to the vagus nerve through the skin, resulting in a reduction of pain.

According to electroCore, the FDA decision was based in part on the results of two clinical trials, which compared outcomes in patients with episodic cluster headache who received VNS or sham. one trial of 85 patients with episodic cluster headache found that 34.2% of patients experienced a reduction in pain from episodic cluster headache compared with 10.6% in patients treated with placebo. A second trial of 27 patients with episodic cluster headache found that a significantly higher percentage of patients using gammaCore reported being “pain-free” within 15 minutes of using the technology at the onset of pain from cluster headache (47.5%) versus placebo (6.2%). In both trials, gammaCore was found to be safe and well-tolerated, with most adverse events being mild and transient.
 

Advertisement
Advertisement
 
 

TEST YOUR KNOWLEDGE

Which of the following is a true statement about management of delirium in an inpatient setting?

A. Pharmacological intervention is indicated even in mild delirium that does not cause sleep disturbance or interfere with medical treatment.

B. For delirium lasting longer than seven days, providers should consider substance withdrawal as the likely cause.

C. Rooms should be kept dimly lit to avoid overstimulating the patient.

D. Mechanical restraints should be used in preference to sitters, because bedside companions often exacerbate confusion.

E. Patients should be frequently reoriented to time, place, and staff members.

Click HERE to answer


Advertisement
Advertisement
 
PSYCHOPHARM NEWS FROM AJP

Monitoring of Patients on Second-Generation Antipsychotics: A National Survey of Child Psychiatrists
READ MORE


Diabetes Prevalence Among Racial-Ethnic Minority Group Members With Severe Mental Illness Taking Antipsychotics: Double Jeopardy?
READ MORE



Have a topic that you would like to see addressed in an article in PsychoPharm? Send your suggestions to Jennifer Carr at jcarr@psych.org.

PsychoPharm Editorial Advisory Board
Philip Muskin, M.D., Columbia University Medical Center (Editor)
Anna Dickerman, M.D., Weill Cornell Medical College
Petros Levounis, M.D., M.A., Rutgers New Jersey Medical School
Jonathan Meyer, M.D., University of California, San Diego
Beth Salcedo, M.D., The Ross Center for Anxiety and Related Disorders, Washington, D.C.
Erin Zerbo, M.D., Rutgers New Jersey Medical School



Copyright © 2017 American Psychiatric Association. All rights reserved.

Important information: You are receiving this correspondence because you have previously requested to receive information via email. To unsubscribe to this electronic newsletter, please click here. Please do not reply to this email, as we are unable to respond to messages sent to this address. You can send your comments or questions to jcarr@psych.org. The content of Psychiatric News does not necessarily reflect the views of APA or the editors. Unless so stated, neither Psychiatric News nor APA guarantees, warrants, or endorses information or advertising on this site. Clinical information is not peer reviewed and thus should be independently verified. Privacy Policy.
Advertisement